Intermediate-stage HCC - Upfront resection can be feasible

Nature Reviews Clinical Oncology

Volumn 12, Issue 5, 2015, Pages 295-296

  Zhong, Jian Hong ^a   Lu, Shi Dong ^a   Wang, Yan Yan ^a   Ma, Liang ^a   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT;

ABLATION THERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; DRUG COST; DRUG EFFICACY; HUMAN; LETTER; LIVER CELL CARCINOMA; LIVER RESECTION; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SAFETY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS;

EID: 84928824561     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.122-c3     Document Type: Letter

References (17)

1. Forner, A., Gilabert, M., Bruix, J. & Raoul, J. L. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 11, 525-535 (2014).
2. Llovet, J. M., Bru, C. & Bruix, J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver. Dis. 19, 329-338 (1999).
3. Llovet, J. M. & Bruix, J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37, 429-442 (2003).
4. Zhong, J. H. et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann. Surg. 260, 329-340 (2014).
5. Oliveri, R. S., Wetterslev, J. & Gluud, C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD004787. http://dx.doi. org/10.1002/14651858.CD004787.pub2 (2011).
6. Kudo, M. et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 29, 339-364 (2011).
7. European Association for The Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
8. Malagari, K. et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc. Intervent. Radiol. 35, 1119-1128 (2012).
9. Burrel, M. et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design. J. Hepatol. 56, 1330-1335 (2012).
10. Salem, R. et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-Term outcomes. Gastroenterology 138, 52-64 (2010).
11. Bruix, J. et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J. Hepatol. 57, 821-829 (2012).
12. Lencioni, R. et al. GIDEON (global investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafenib): second interim analysis. Int. J. Clin. Pract. 68, 609-617 (2014).
13. Beaugrand, M. et al. Treatment of advanced hepatocellular carcinoma by seocalcitol (a vit D analogue): an international randomized double-blind placebo-controlled study in 747 patients [abstract 37]. J. Hepatol. 42 (Suppl. 2), 17 (2005).
14. Zhong, J. H., Wu, F.X & Li, H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol. 35, 8355-8358 (2014).
15. Yin, L. et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J. Hepatol. 61, 82-88 (2014).
16. Zhong, J. H. et al. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) 94, e396 (2015).
17. Zhong, J. H. et al. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS ONE 9, e108755 (2014).